ABO血型系统
医学
兄弟姐妹
地中海贫血
脐带
移植
造血干细胞移植
内科学
单变量分析
脐带血
免疫学
儿科
多元分析
心理学
发展心理学
作者
Selime Aydoğdu,Ersin Töret,Başak Adaklı Aksoy,Muhammed Fatih Aydın,Funda Çipe,Ceyhun Bozkurt,Tunç Fışgın
出处
期刊:Hemoglobin
[Informa]
日期:2021-01-02
卷期号:45 (1): 25-29
被引量:3
标识
DOI:10.1080/03630269.2021.1872611
摘要
Allogeneic hematopoietic stem cell transplantation (HSCT) is the curative therapy for β-thalassemias that induces severe life-threatening complications. The human leukocyte antigen (HLA) registries and umbilical cord blood banks have carried out diligent searches to find matched unrelated donors (MUDs) for about 70.0% of patients from 2000 onwards. The chance of finding a non-sibling fully matched family donors is higher in some ethnic groups in which consanguineous marriages are common. We have studied and compared transplant complications and outcomes in different graft types (sibling, non-sibling family and unrelated). The non-sibling matched family donor (MFD) group consisted of four mothers, three fathers, five cousins, one paternal uncle and one paternal aunt. There was no significant difference in the mean transfused CD34+ cells, engraftment, median days of neutrophil and platelet recovery were achieved (p > 0.05). The distribution of postttransplant complication did not show any significant difference between groups (p > 0.05). In univariate analysis and multivarite analyses, age, gender, Pesaro risk group (I-II vs. III) and ABO incompatibilty demonstrated a significant difference in disease free survival (p < 0.05). Furthermore, in the second step of investigating overall survival (OS), age, gender and Pesaro risk group (I-II vs. III) showed a significant difference (p < 0.05). There was no significant difference in transplant-related mortality (TRM) between groups. Non-sibling related donor transplants are important for populations where consanguineous marriages are common. Transplant groups according to graft type had similar thalassemia-free survival (TFS) and OS when using a treosulfan-based regimen in our study.
科研通智能强力驱动
Strongly Powered by AbleSci AI